Study: Epo is well tolerated in neonates with HIE

11/16/2012 | Medscape (free registration)

Early trial data showed erythropoietin, given in addition to hypothermia treatment, was well tolerated and may be neuroprotective for neonates with hypoxic-ischemic encephalopathy. Researchers at the University of California, San Francisco, said they plan to do a large randomized trial of Epo that will follow infants for two years to evaluate neurologic outcomes.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR